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Radiation therapy in older patients
Abstract
As average population life span increases number of people of older age
affected with malignant tumours also increases which became significant
public health issue. Main modalities in treating cancer are surgery, chemo-
therapy and radiation therapy. They can be used either alone or in various
combinations depending on tumour type, grade of a disease, patient’s
condition etc.
Current radiation therapy techniques give the possibility to deliver
radiotherapy more precisely and with higher doses to the tumour meanwhile
protecting surrounding tissue and preserving the physiological function of
the regions in the body not involved with tumour. In this way it is possible to
deliver curative doses of radiation therapy in older patients without com-
promising their general health and conserving the life quality in satisfactory
manner. Subject of this work is clinical implementation of advanced radi-
ation therapy techniques for the cancer treatment of older patients. Thus,
different systems of assessment of overall patient performance were intro-
duced and radiotherapy of most common cancer types in elderly population
was reviewed and discussed.
INTRODUCTION
As some data indicate, the incidence of malignant tumours in po-pulation over 85 years of age rises over 3.5 % (1,2,3). Consequently
the percentage of people of older age affected with malignant tumours
will also rise in time which is significant public health issue. Cancer
treatment in older patients is often complicated and challenging but it
could be as helpful as for younger patients. Bearing this in mind, each
case must be analysed separately. Diagnostic medical data regarding the
type and extent of disease, available treatment options, quality of life
during and following the treatment, the risks and benefits of treatment,
patients’ choice of treatment as well as financial and social aspects of the
treatment must be considered prior defining treatment of choice (4,5,6).
External beam radiation therapy (EBRT) is one of the efficient treat-
ment modalities and as such it would be the subject of this paper.
CANCER TREATMENT MODALITIES AND OLDER
POPULATION
Due to fear of acute side effects and impact on life quality the
approach in treating older patients with cancer is often less aggressive
and radical then it really might be. Nevertheless, in the majority of
papers (2,7) discussing radiotherapy issues in older people there is no
evidence of higher adverse event onset in the evaluated population if
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Overview
Cancer treatment usually consists either of a single
therapy modality or a combination of modalities. This
can include surgery, chemotherapy and radiotherapy.
The supportive care is also a valid option for patients who
cannot or do not want to undergo an active treatment.
The aim of such a treatment is to provide palliation of
symptoms like pain and inappetence and to give a patient
better life quality. Giving support to the family of patient
plays also an important role in the integral oncological
treatment.
Radiation therapy is modality of localized treatment
and is applied alone or in various combinations with
surgery and chemotherapy. Radiotherapy can be external
(external beam radiation therapy-EBRT) meaning that
is applied using high energy photon or charge particles
beams or internal by placing radioactive sources in tu-
mours or body cavities near the tumour volume. Patients
mostly receive this kind of treatment as outpatients and
most often there is no need for hospitalization. The
treatment, given as a radical one, has duration of several
weeks.
ASSESSMENT OF ELDERLY PATIENT
PERFORMANCE STATUS
In the assessment of overall patient performance dif-
ferent systems are currently in use. Most widespread are
ECOG (Eastern Cooperative Oncology Group) perfor-
mance scale (8) and Karnofsky performance index. The-
se systems may under-evaluate the scale of functional
damage in older people because of their descriptive and
general nature of enquiring everyday activities and health
state. Therefore, other more detailed evaluation systems
should be used, i.e. ADL (Activities of Daily Living
scale) (9) which can allow us to precisely evaluate the
psychophysical condition of the patient. This assessment
tool is divided in three subcategories – BADL (Basic
Activities of Daily Living), IADL (Intermediate Acti-
vities of Daily Living) and AADL (Advanced Activities
of Daily Living).
BADL evaluates independence and ability of full sca-
le basic self-care like feeding, fulfilling hygienic needs,
dressing etc. IADL evaluates ability of doing everyday
activities like preparing food, driving, going to shopping,
using public transportation etc. AADL looks at complete
familiar and social involvement of individual and involv-
ement in different recreational or voluntary groups and
actions (10). The assessment of functional status of
elderly people is just a part of the overall assessment
which includes familiar state, social state, economical
state, educational state, cognitive functions and other
characteristics.
RADIATION THERAPY
Clinical implementation of radiation therapy for the
cancer treatment is rather complex process which includ-
es use of highly sophisticated equipment (e.g. linear
accelerator, computed tomography simulator, treatment
planning system, portal imaging device…) and different
positioning and immobilization systems. Furthermore,
from the prescription to the delivery of radiotherapy
treatment a team of professionals from a number of
disciplines is involved in a large number of steps, which
makes a significant potential for errors (11,12). Thus,
clinical implementation of advanced radiation therapy
techniques should be prepared seriously and with great
care. For example, at University Hospital Rijeka the cli-
nical implementation of advanced techniques has been
started following participation of Radiotherapy depart-
ment in Quality Audit in Radiation Therapy (QUATRO)
(13) organized by International Atomic Energy Agency.
The system has been developed according to the guide-
lines provided by the team of auditors and it has been
upgraded permanently. Due to high level of complexity,
functionality of each and every part of the system must be
controlled and verified periodically. Therefore, compre-
hensive quality assurance/quality control (QA/QC) pro-
gramme is required to assure treatment outcome and
radiation safety of the patient (14,15). In other words,
after all assumptions for the successful delivery of radio-
therapy have been satisfied and the process of delivering
the treatment commenced, frequent quality control has
to be implemented and conducted to minimize possible
adverse events in all patients. Such procedures must take
into account everything from daily recording and veri-
fying the positioning of the patient on treatment couch,
dose delivery and accuracy of the equipment for radio-
therapy planning and delivery.
Clinical application of advanced radiation techniques
(3 Dimensional Conformal Radiation Therapy and In-
tensity Modulated Radiation Therapy) brings significant
improvement due to possibility of applying higher cu-
mulative doses with sparing of healthy tissue and organs
at risk. Nevertheless, at the same time the preparation of
the treatment is quite complex and time consuming. It
includes CT simulation with acquisition of patient ana-
tomy data in the treatment position. Based on acquired
anatomical data the process continues with contouring
of target volumes and organs at risk (16,17) which is
followed by the complex calculations of dose distribu-
tions and creation of the treatment plan according to, so
called, dose volume constraints (DVC) (18). Treatment
plan evaluation requires knowledge of the effect of the
radiation, not only on the intended target, but also the
surrounding normal tissues. Literature brings estima-
tions of tolerance doses and proposed dose-volume con-
straints for many of the organs at risk (18). Technological
advances have brought in wide use the 3 dimensional
radiotherapy planning systems with advanced algori-
thms (19) and possibility of more accurate and precise
calculation of dose distributions. Those calculations are
used for the treatment plan optimization.
CLINICAL APLICATION OF
RADIOTHERAPY IN OLDER POPULATION
A majority of elderly patients are usually not can-
didates for surgical treatment due to several reasons (age,
comorbidities, patient wishes and preferences). There-
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fore, external beam radiation therapy is the treatment of
choice. According to our clinical experience it gives better
overall survival then best supportive care in patients who
cannot undergo a surgical procedure. One has to bear in
mind that more than 80% of elderly people have two or
more comorbidities thus the evaluation of comorbidities
and seriousness of such conditions is extremely import-
ant in evaluating the possibility of radical radiation treat-
ment. Patients, who are evaluated as those who could
have serious adverse events of radiation therapy or those
who have serious comorbidities and because of that short
life expectance, should not get radical radiation treat-
ment. The most commonly used tools for assessment of
comorbidity risks are ACE-27 (20) scale and Charlson
comorbidity index (21).
Modern technological advances made possible to vi-
sualise the target areas, contour them in computer based
radiotherapy planning systems and calculate accurate
and precise dose distributions plans. Digital linear ac-
celerators with multileaf collimators makes conforming
of radiation fields to the shape of target volume possible
allowing the radiation oncologist to raise the dose plan-
ned on target volume. Consequently, radiotherapy can be
delivered more precisely and with higher doses to the
tumour meanwhile protecting surrounding tissue and
preserving the physiological function of the regions in
the body not involved with a disease. In this way it is
possible to deliver curative doses of radiation therapy in
older patients without compromising their general health
and conserving the life quality in satisfactory manner.
Regarding the available data in literature there is no
indication for a dose reduction in radiation therapy only
because of age, especially in the curative setting (2,7,22).
Older adults usually withstand radiation therapy well
and the side effects of radiation therapy are more depen-
dent on the type of radiation treatment, dose delivered
and location of the cancer being treated than on the age.
It is also crucial for the treatment outcome that the
positioning of the patient during 30–35 daily fractions of
the treatment mimics the initial one. Thus the immo-
bilization of the patient is very important and different
kinds of positioning and immobilization devices are used
for day to day treatment reproducibility.
Three most common types of carcinoma in elderly
population (23) usually treated with radiotherapy are
breast cancer, lung cancer and prostate cancer. The breast
carcinoma is the most common type of cancer in femi-
nine population (23). Standard adjuvant therapy scheme
usually includes radiotherapy. Radiation therapy in wo-
men treated with breast conserving surgery is typically
delivered to the whole (entire) breast. The standard dose
to the breast after lumpectomy is 50 Gy in 2 Gy daily
fractions with the addition of a boost dose to tumour bed
for the appropriate group of patients which ranges from
10–16 Gy in 2 Gy daily fractions. Therapy is applied via
two angled (tangential) beams designed to minimize
dose to the underlying normal lung tissue or using ad-
vanced planning (3DCRT or IMRT) with photon beams.
Boost dose can be delivered in different ways, either with
photon beams using 3DCRT, electron beams or using
interstitial brachytherapy technique. Post mastectomy
irradiation is applied to the chest wall as well as to the
regions of possible lymphatic spread of the tumour de-
pending on histological findings. The dose given in this
case is 50 Gy in 2 Gy daily fractions. Radiation is usually
delivered by tangential photon beams or direct appo-
sitional electron field. This kind of treatment is also
applied in the older patient population with the same
doses and techniques above mentioned.
It has been proven that adjuvant radiotherapy reduces
the risk of breast cancer recurrence and death as a result
of breast cancer. In the update of the Early Breast Cancer
Trialists’ Group metaanalysis, radiotherapy lowered the
risk of breast cancer recurrence by about one half and
lowered the risk of breast cancer death by one sixth (24).
It has been observed that the benefit of radiotherapy is
correlated with the initial risk assessment for the recur-
rence of disease and has also been observed that the
patients with low risk breast cancer did not have benefit
from radiotherapy as those with high risk for recurrence.
The CALGB 9343 trial was designed to answer the
above raised question analyzing the subset of older wo-
men with low-risk breast cancer. This study has been
conducted on more than 600 women aged 70 or older
with the disease assessed as having a low risk for recur-
rence. Study had two arms, one in which patients have
been treated with tamoxifen and the other in which they
have been treated with tamoxifen and adjuvant radio-
therapy. The study results showed no significant dif-
ference in the rates of subsequent mastectomy, distant
metastases, or overall survival between the two groups.
The study has been initially published in 2004. with the
median follow-up of five years and the rate of local or
regional recurrence was 1 % in the radiation group and
4% in the group not treated with radiation. Study has
been updated after 10.5 years follow up period and it has
been shown that the local disease recurrence was inferior
in the group receiving adjuvant radiotherapy (2 % vs. 9
%) (25).
In the light of the described studies and principles it
can be concluded that the radiotherapy of breast carci-
noma has proven benefits in older patient population.
In the breast radiotherapy it should be taken into
account that organs at risk are lungs, hearth and spinal
cord, which if compromised by radiotherapy can sig-
nificantly lower the life quality of older patient and raise
the comorbidity and non cancer related death rate. The-
refore, it is crucial to determine the risk for breast cancer
recurrence based on clinical and hystological findings
and possibly apply adjuvant radotherapy in patients
whose disease is evaluated as having a high risk for
recurrence.
Patients with newly diagnosed lung cancer in more
than 50 % cases are of age 70 or higher (26). The pre-
valence of comorbidity among lung cancer patients is
significantly higher in patients aged higher than 70 years,
together with a proportionate in cases in the number of
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comorbidities per patient (27). The rate of disease diag-
nosed in early stage is considerably lower in older popu-
lation then in younger individuals and as such prog-
nostically unfavourable. Despite the rising incidence of
lung cancer with age, discrimination on the basis of age
occurred occasionally. The elderly obtain lower histo-
logical confirmation rates (28,29), less accurate staging
and lower rates of radical treatments despite more than
50 % of lung cancer patients aged 65 years or more have
good or excellent performance status (28). Concurrent
chemoradiotherapy is now the standard of care for pati-
ents with stage III non-small cell and limited disease-
-small cell lung cancer. More than half of this patients
were not eligible for concurrent chemoradiotherapy on
the basis of criteria of age and important comorbidities
(30).
Current standard doses for the radical chemoradio-
therapy are in range of 60–70 Gy in 2 Gy daily fractions.
Also the results of recent phase III study shows that
further dose increase has no influence on overall survival
(31) of the patients with stage III non- small cell lung
cancer treated with concurrent chemoradiotherapy. The-
refore, for this group of patients the treatments of choice
are either sequential chemoradiotherapy or radiotherapy
alone with total doses up to 70 Gy. Thus the strict imple-
mentation of dose volume constraints in radiotherapy
treatment and the consideration of the age of the patient
and general physiological decrease of functionality of
different organ systems are of extreme importance.
Further developments in technology introduced 4D
CRT (32) techniques in clinical use which combines
respiratory gating (delivering the radiation therapy in a
certain moment of respiratory cycle and thus enabling
the delivery of treatment to the same geometric area
every time independent of the movement of thoracic
wall) (33). Stereotactic ablative radiotherapy (SART) is
the novel technique recently implemented in clinical
use. It is based on a concept of delivery of a large dose in a
short time period to a very limited target volume in stage
I lung cancer patient. This method may replace surgical
procedures due to possibility of very high dose delivery.
Some current clinical studies have demonstrated impro-
vement in survival in patients treated with SART com-
pared to 3D-CRT (34). It has to be stressed that this kind
of treatment requires a highly sophisticated technology
and appliances with excellent logistics. Also the cost of
this type of therapy is much higher compared with stan-
dard 3D CRT. Regarding this it is not widespread clini-
cally implemented at the moment.
The other most common tumour type in elder male
population is the prostate carcinoma, the second most
common (23) type of cancer in male population in Cro-
atia which correlates with epidemiological data from
other countries worldwide.
Prostate carcinoma may be treated in several ways
including surgery, hormonal therapy and radiotherapy.
Every treatment modality has its own drawbacks and
risks, especially in older population. Nevertheless, due to
quite favourable side effect profile radiotherapy may be
the most appropriate way of treating this entity. Further-
more, radiotherapy of prostate carcinoma shows signi-
ficant advantages over surgical treatment because of avo-
iding complications like in- and post- surgery bleeding,
risks related to blood transfusion, infections, urinary in-
continence and anaesthesia related risks in cardiovas-
cular and respiratory system (myocardial infarction, pul-
monary embolism etc.).
In the past 20 years a major breakthrough has been
made in radiotherapy of prostate carcinoma. In 1980s the
standard routine was a 2D (two dimensional) treatment
planning which allowed the administration of radio-
therapy in the dose range of 66–70 Gy due to acute and
chronic post radiotherapy toxicities. Therefore, Kuban et
al. (35) conducted a dose escalation study in prostate
carcinoma radiotherapy. It was performed randomizing
301 patients with different disease stage in two study
groups. One group received total dose of 78 Gy on target
volume while the dose to the target volume in other
group was 70 Gy. It was reported (35) that the group
receiving higher total dose had a significantly longer
progression free period (biochemical and clinical, 78 %
versus 59 %, p=0.004). These results lead the radiation
oncologist community to conclusion that doses of up to
70 Gy are inadequate for the treatment of prostate car-
cinoma.
Considering the prostate carcinoma radiotherapy or-
gans at risk which limit the total dose are bladder, colon
and small intestine. These limitations can be dealt with
by the implementation of advanced radiotherapy tech-
niques and the corresponding toxicities and side effects
of the treatment can be reduced (36). The standard doses
with these techniques are in the range of 74–78 Gy
applied in 7–8 weeks of treatment. Further advances in
technology have brought in clinical use intensity modu-
lated radiotherapy (IMRT) and volumetric modulated
arc therapy (VMAT). This consequently allows further
escalation of the total dose to 80 Gy. Also it has been
demonstrated that despite the increase of the dose, using
this methods the risk of gastrointestinal toxicities (36)de-
creased. Nevertheless, time per fraction in those tech-
niques is significantly longer comparing with 3D con-
formal radiotherapy. This is usually the problem for older
patients due to maintaining exact patient position during
prolonged treatment time. Regarding this 3D conformal
radiotherapy remains the treatment of choice for older
patients in most cases.
CONCLUSION
Radiotherapy in older patient population represents a
viable and reasonable treatment option in integral cancer
treatment. Radical radiotherapy treatment can be defi-
nitive and curative therapy and it has to be applied in
adequate dose levels and fractionation. It has its own
drawbacks and possible risks. Regarding this, it is very
important to evaluate every individual patient regarding
patient’s performance status, comorbidities, clinical find-
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ings and tumour characteristics. Applying this personally
“tailored” approach to therapy the possible risks for health
deterioration and life quality disruptance can be dimi-
nished to acceptable levels. Fulfilment of all this pre-
sumptions allows applying high quality radiotherapy
treatment for patients of older age.
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